Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.
One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.
TriSalus Life Sciences director David J. Matlin reported equity compensation grants. He received 23,065 restricted stock units that vest in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.
He also received 28,201 restricted stock units in lieu of 2026 board service retainer cash fees; these vest in three equal quarterly installments through the remainder of 2026, subject to continued service. In addition, he was granted options to purchase 56,403 shares of common stock at an exercise price of $2.52 per share, vesting in full on the one-year anniversary of the May 14, 2026 grant date. Following these awards, Matlin directly holds 1,323,210 shares of common stock and 121,403 stock options.
TriSalus Life Sciences director William Valle reported equity compensation grants. He received 24,553 restricted stock units and 28,201 additional restricted stock units, both payable in common stock. One award is in lieu of 2026 board retainer cash fees and vests in quarterly one-third installments through 2026.
Valle was also granted a director stock option for 56,403 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036. The RSU awards and option generally vest on the one-year anniversary of the May 14, 2026 grant date, subject to his continued service with the company.
TriSalus Life Sciences director Michael P. Stansky reported new equity awards and updated holdings. He received two grants of restricted stock units covering 20,089 and 23,501 shares of common stock, both payable solely in stock. One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date, while the retainer RSU award vests in three equal quarterly installments through the remainder of 2026, each subject to his continued board service.
He was also granted a director stock option for 47,003 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036, which will fully vest one year after the grant date if he continues serving. Following these grants, he holds 830,722 common shares directly and 199,698 shares indirectly through Skyview Investments LLC, where he serves as managing member with voting and dispositive power, along with 139,540 director stock options.
TriSalus Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders. A total of 41,728,676 shares of common stock, representing 67.9% of outstanding shares, were present or represented, providing a solid quorum for the meeting’s business.
Stockholders elected Mary Szela and Gary Gordon as directors to serve three-year terms expiring at the 2029 annual meeting. The appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026 was also ratified by a wide margin.
On executive compensation matters, stockholders approved a three-year frequency for future advisory votes on named executive officer pay, and approved the current compensation of named executive officers on an advisory basis. Following the vote, the Board decided the company will hold say-on-pay votes every three years.
TriSalus Life Sciences, Inc. reported first‑quarter 2026 revenue of $8.9 million, slightly below the prior year’s $9.2 million, but generated net income of $1.5 million versus a $10.4 million loss a year earlier. The swing to profit was driven mainly by non‑cash gains from remeasuring warrant, earnout and revenue‑based redemption liabilities.
Gross profit held essentially flat at $7.7 million, while operating expenses rose modestly as the company continued investing in R&D and commercial growth for its PEDD delivery systems and nelitolimod. Cash and cash equivalents increased sharply to $56.6 million, primarily from a February equity offering that raised about $42.6 million net.
Total assets doubled to $71.0 million, and stockholders’ equity improved from a deficit of $33.9 million at year‑end 2025 to positive equity of $12.8 million at March 31, 2026. Long‑term debt under the OrbiMed credit facility remained around $33.1 million, with associated warrants and revenue‑based redemption obligations continuing to be marked to fair value each quarter.
TriSalus Life Sciences, Inc. reported first‑quarter 2026 revenue of $8.9 million, slightly below the prior year’s $9.2 million, but generated net income of $1.5 million versus a $10.4 million loss a year earlier. The swing to profit was driven mainly by non‑cash gains from remeasuring warrant, earnout and revenue‑based redemption liabilities.
Gross profit held essentially flat at $7.7 million, while operating expenses rose modestly as the company continued investing in R&D and commercial growth for its PEDD delivery systems and nelitolimod. Cash and cash equivalents increased sharply to $56.6 million, primarily from a February equity offering that raised about $42.6 million net.
Total assets doubled to $71.0 million, and stockholders’ equity improved from a deficit of $33.9 million at year‑end 2025 to positive equity of $12.8 million at March 31, 2026. Long‑term debt under the OrbiMed credit facility remained around $33.1 million, with associated warrants and revenue‑based redemption obligations continuing to be marked to fair value each quarter.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million from its TriNav system, a 2.9% decrease from the same period in 2025, while gross margin improved to 86.2% from 83.7% as unit costs fell.
Operating loss widened slightly to $8.4 million, driven mainly by higher sales and marketing and stock-based compensation tied to commercial expansion. However, changes in the fair value of derivatives and earnout liabilities produced non-cash gains of $11.3 million, turning results into net income of $1.5 million, or $0.03 per share, versus a prior-year loss.
On a non-GAAP basis, adjusted EBITDA loss was $5.8 million, modestly higher than a year ago. The company raised $46.0 million in gross proceeds from an equity offering, ending March 31, 2026 with $56.6 million in cash and cash equivalents. Management revised 2026 revenue guidance to a range of $54 million to $57 million and highlighted ongoing clinical and commercial progress for its PEDD platform and nelitolimod program.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million from its TriNav system, a 2.9% decrease from the same period in 2025, while gross margin improved to 86.2% from 83.7% as unit costs fell.
Operating loss widened slightly to $8.4 million, driven mainly by higher sales and marketing and stock-based compensation tied to commercial expansion. However, changes in the fair value of derivatives and earnout liabilities produced non-cash gains of $11.3 million, turning results into net income of $1.5 million, or $0.03 per share, versus a prior-year loss.
On a non-GAAP basis, adjusted EBITDA loss was $5.8 million, modestly higher than a year ago. The company raised $46.0 million in gross proceeds from an equity offering, ending March 31, 2026 with $56.6 million in cash and cash equivalents. Management revised 2026 revenue guidance to a range of $54 million to $57 million and highlighted ongoing clinical and commercial progress for its PEDD platform and nelitolimod program.
TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.
TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.
TriSalus Life Sciences, Inc. announced that Jodi Devlin has notified the company of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The company previously appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, helping support continuity in its clinical and medical leadership.
Frankenius Equity AB, a more than 10% holder of TriSalus Life Sciences, Inc., converted its entire Series A Convertible Preferred Stock into common shares. On July 31, 2025, it exchanged 230,000 preferred shares for 759,000 shares of common stock under a company exchange offer.
The offer calculates common shares using the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares, replacing its prior preferred position with ordinary equity.